Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
J. Clin. Oncol 2020 May 13;[EPub Ahead of Print], LJ Nastoupil, MD Jain, L Feng, JY Spiegel, A Ghobadi, Y Lin, S Dahiya, M Lunning, L Lekakis, P Reagan, O Oluwole, J McGuirk, A Deol, AR Sehgal, A Goy, BT Hill, K Vu, C Andreadis, J Munoz, J Westin, JC Chavez, A Cashen, NN Bennani, AP Rapoport, JM Vose, DB Miklos, SS Neelapu, FL LockeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.